Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection

The Strata Trial is a precision oncology collaboration structured as an observational master
screening protocol with the aim to match patients to genomically-guided therapeutic protocols
and/or approved therapies. Subjects enrolled on the Strata trial will submit surplus,
clinical formalin fixed paraffin-embedded (FFPE) tumor specimens for molecular profiling and
a test report will be provided back to the investigator. For those subjects identified as
having molecular variants associated with an affiliated therapeutic protocol and/or approved
targeted therapy, the Strata report will provide additional relevant information.

All molecular profiling will be performed in the Strata Oncology CLIA-certified laboratory
(Ann Arbor, MI). The molecular profiling assays will include targeted next generation
sequencing (NGS) of DNA and RNA covering a range of actionable genomic variants, such as gene
mutations (e.g. those in EGFR and BRAF), gene amplifications (e.g. ERBB2) and gene fusions
(e.g. ALK).

Subjects who have been identified with genetic alterations relevant to a trial or targeted
therapy will be followed for treatment changes for three years from the time of signed
informed consent.

Inclusion Criteria:

- Subjects must be ≥ 18 years of age.

- Subjects must have histologically documented solid tumors or lymphoma.

- Specific criteria for individual tumor types are as follows:

1. Subjects with glioblastoma.

2. Subjects with pancreatic cancer are eligible at any stage of disease.

3. Subjects with rare tumors (i.e. cancer started in an unusual place in the body,
it is unusual type and requires special treatment) are eligible at stages II-IV

4. Subjects with other tumor types must have recurrent, relapsed, refractory,
metastatic or advanced stages III or IV cancer.

- Subjects must have an adequate formalin-fixed paraffin-embedded tumor specimen for
genomic sequencing.